RxDoctor Payments Data

Christen McCabe

Family · Athens, GANPI 1659983948

Payments from drug & device makers

$11,851in general payments, 2019–2025

Across 210 payments — averaging $56.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$7K
  • United Therapeutics Corporation$687
  • Boehringer Ingelheim$664
  • AstraZeneca$456
  • GSK$422
  • Bayer$309
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$4,50638%
  • Travel & lodging$1,99817%
  • Food & beverage$5,26144%
  • Education$851%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,851 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$2,052
Medicare patients
42
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$147,744
Breo ElliptaFluticasone/Vilanterol68$37,033
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$34,156
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr56$28,611
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$16,094
EliquisApixaban14$15,542
Advair HfaFluticasone Propion/Salmeterol12$10,613
SymbicortBudesonide/Formoterol Fumarate37$10,191
Incruse ElliptaUmeclidinium Bromide20$6,623
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,196
Albuterol Sulfate HfaAlbuterol Sulfate123$3,380
Arnuity ElliptaFluticasone Furoate13$3,136
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,865
Montelukast Sodium99$873
Ventolin HfaAlbuterol Sulfate13$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$422$223,146310 claims
AstraZenecaBreztri Aerosphere, Symbicort$456$44,34878 claims
Boehringer IngelheimStiolto Respimat$664$16,09427 claims
PfizerEliquis$15$15,54214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →